Literature DB >> 19811264

Retinoid X receptor beta polymorphisms do not explain functional differences in vitamins D and A response in Antineutrophil cytoplasmic antibody associated vasculitis patients.

Anna-Isabelle Kälsch1, Anthea Peters, Birgit Buhl, Annette Breedijk, Katharina Prem, Wilhelm H Schmitt, Christel Weiss, Peter Heeringa, Cees Kallenberg, Rainer Birck, Benito A Yard.   

Abstract

It has been suggested that the retinoid X receptor beta (RXRB) gene is a risk factor for Wegener's granulomatosis. We addressed if there is a functional difference in the response to retinoic acid (RA) and vitamin D in Antineutrophil cytoplasmic antibody (ANCA) associated systemic vasculitis (AASV) patients and if this was associated with RXRB genotypes. TNFalpha and IL-10 production were measured in whole blood assay from AASV patients (n = 51) and healthy controls (HC, n = 67). One micromolar of 1,25-(OH)(2) D3, 9-cis RA (9c-RA) or all-trans RA (ATRA) was added to the assay. Genotyping was performed for exons 7 and 2 of the RXRB gene and for a microsatellite in vicinity of the RXRB gene. Lipopolysaccharide (LPS) mediated TNFalpha production and IL-10 were significantly lower in patients. Addition of 1,25-(OH)(2) D3, ATRA or 9c-RA, blunted TNFalpha production, more pronounced in patients. Although all three compounds inhibited IL-10 production significantly in HC, only 1,25-(OH)(2) D3 was found to be effective in patients. Allele distribution of the RXRB microsatellite differed significantly between patients and HC. This was not found for the SNP in exons 2 and 7. Genotype of the latter correlated with the ability of 1,25-(OH)(2) D3 and ATRA to inhibit IL-10 production. We provide immunological evidence for a functional difference in vitamins D and A responsiveness in AASV patients. Since the inhibition of TNFalpha was more effective in patients, vitamin D supplementation might be an additional therapeutical approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19811264     DOI: 10.1080/08916930902960347

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  6 in total

Review 1.  Genetics of ANCA-associated Vasculitides.

Authors:  Manuel F Ugarte-Gil; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2014-07       Impact factor: 4.592

2.  The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset.

Authors:  Mark A Little; Lina Zgaga; Jennifer Scott; Enock Havyarimana; Albert Navarro-Gallinad; Arthur White; Jason Wyse; Jos van Geffen; Michiel van Weele; Antonia Buettner; Tamara Wanigasekera; Cathal Walsh; Louis Aslett; John D Kelleher; Julie Power; James Ng; Declan O'Sullivan; Lucy Hederman; Neil Basu
Journal:  Arthritis Res Ther       Date:  2022-06-18       Impact factor: 5.606

Review 3.  Potential role of nuclear receptor ligand all-trans retinoic acids in the treatment of fungal keratitis.

Authors:  Hong-Yan Zhou; Wei Zhong; Hong Zhang; Miao-Miao Bi; Shuang Wang; Wen-Song Zhang
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

4.  Serum vitamin D level correlates with disease activity and health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  T Yoon; S S Ahn; J Y Pyo; J J Song; Y-B Park; S-W Lee
Journal:  Z Rheumatol       Date:  2020-12-18       Impact factor: 1.372

5.  Genetic Variants in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Approach and Systematic Review.

Authors:  Kwang Seob Lee; Andreas Kronbichler; Daniel Fernando Pereira Vasconcelos; Felipe Rodolfo Pereira da Silva; Younhee Ko; Yeon Su Oh; Michael Eisenhut; Peter A Merkel; David Jayne; Christopher I Amos; Katherine A Siminovitch; Chinar Rahmattulla; Keum Hwa Lee; Jae Il Shin
Journal:  J Clin Med       Date:  2019-02-21       Impact factor: 4.241

Review 6.  Environmental factors influencing the risk of ANCA-associated vasculitis.

Authors:  Wen-Man Zhao; Zhi-Juan Wang; Rui Shi; Yu-Yu Zhu; Sen Zhang; Rui-Feng Wang; De-Guang Wang
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.